ABP234 and Keytruda in subjects with Stage IV NSCLC
A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda (Pembrolizumab) in Subjects with Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer (20210033)
Disease Types: Lung
Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville
A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda (Pembrolizumab) in Subjects with Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer (20210033)
For More Information: